[Severe preeclampsia: management. Is conservative treatment justified?].
Severe preeclampsia is a major contributor to maternal and perinatal morbidity and mortality. This review was performed to assess the fetal and maternal benefits of allowing women presenting with severe preeclampsia between 24 and 32-34 weeks of amenorrhea to continue their pregnancy following antihypertensive treatment. After ultrasound scanning to assess growth and biophysical state of the fetus, patients without deteriorating maternal conditions, were managed with volume expansion, antihypertensive drugs (as hydralazine, labetalol, nifedipine), anticonvulsants and prophylactic steroids to promote fetal pulmonary maturity. Previous studies have indicated that this conservative management is also possible with the HELLP syndrome, without an increase in maternal morbidity.
Merviel
P
P
Service de Gynécologie-Obstétrique, Hôpital Tenon, Paris.
Dumont
A
A
Bonnardot
J P
JP
Perier
J F
JF
Rondeau
E
E
Berkane
N
N
Salat-Baroux
J
J
Uzan
S
S
D000927:Anticonvulsants / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003663:Decision Trees; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D018579:Patient Selection; D011225:Pre-Eclampsia / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D011247:Pregnancy; D011256:Pregnancy Outcome; D012720:Severity of Illness Index; D013256:Steroids / Q000627:therapeutic use*; D016216:Ultrasonography, Prenatal
D000927:Anticonvulsants; D000959:Antihypertensive Agents; D013256:Steroids